Shots:

• The exclusive WW collaboration agreement is to evaluate Mustang Bio’ s MB-101 (IL13Rα2-specific CAR) in combination with C134 for the treatment of glioblastoma multiforme
• The focus of the agreement is to assess the combination- inducing anti-tumor immune response when combined with CAR-T therapy targeting solid tumors 
• C134 is a herpes simplex virus type 1 (HSV-1) oncolytic virus- improving replication in tumors and is currently evaluated in P-I for patients with recurrent glioblastoma multiforme

Ref: Mustang Bio | Image: Ihsigns